Atlas Trials

Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab

Clinical trial NCT05188495 · UNKNOWN

Trial details

NCT number
NCT05188495
Sponsor
Peking University Cancer Hospital & Institute
Status
UNKNOWN
Study type
OBSERVATIONAL
HER2-positive Metastatic Breast CancerPreviously Treated With TrastuzumabTrastuzumab Combined With Pertuzumab and Chemotherapy
Start date
2021-05-10
Primary completion
2023-12-10
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.